{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:46:26Z","timestamp":1792233986387,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11523-020-00753-7","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:02:46Z","timestamp":1603360966000},"page":"733-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Julie G.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian C.","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo H.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Veljovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"Crilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen J.","family":"Calfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Thota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Rygiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha L.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"4","key":"753_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neo.2016.03.002","volume":"18","author":"MB Myers","year":"2016","unstructured":"Myers MB, Banda M, McKim KL, Wang Y, Powell MJ, Parsons BL. Breast cancer heterogeneity examined by high-sensitivity quantification of PIK3CA, KRAS, HRAS, and BRAF mutations in normal breast and ductal carcinomas. Neoplasia. 2016;18(4):253\u201363. https:\/\/doi.org\/10.1016\/j.neo.2016.03.002.","journal-title":"Neoplasia"},{"issue":"15_Suppl.","key":"753_CR2","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/jco.2012.30.15_suppl.3106","volume":"30","author":"V Madhusudanannair","year":"2012","unstructured":"Madhusudanannair V, Janku F, Falchook GS, Hong DS, Wheler JJ, Naing A, et al. NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. J Clin Oncol. 2012;30(15_Suppl.):3106. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.3106.","journal-title":"J Clin Oncol."},{"issue":"2","key":"753_CR3","first-page":"1545","volume":"9","author":"YY Jung","year":"2016","unstructured":"Jung YY, Jung WH, Koo JS. BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Int J Clin Exp Pathol. 2016;9(2):1545\u201356.","journal-title":"Int J Clin Exp Pathol"},{"key":"753_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212566","volume":"8","author":"JG Bustamante","year":"2019","unstructured":"Bustamante JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs Context. 2019;8:1\u20135. https:\/\/doi.org\/10.7573\/dic.212566.","journal-title":"Drugs Context"},{"issue":"6","key":"753_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamaoncol.2016.0405","volume":"2","author":"K Wood","year":"2016","unstructured":"Wood K, Hensing T, Malik R, Salgia R. Prognostic and predictive value in KRAS in non-small-cell lung cancer. JAMA Oncol. 2016;2(6):805. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0405.","journal-title":"JAMA Oncol"},{"key":"753_CR6","volume-title":"Principles and practice of gynecologic oncology","author":"R Barakat","year":"2013","unstructured":"Barakat R, Berchuck A, Markman M, Randall ME. Principles and practice of gynecologic oncology. 6th edn. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins; 2013."},{"issue":"7","key":"753_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm. Hum Pathol. 2011;42(7):918\u201331. https:\/\/doi.org\/10.1016\/j.humpath.2011.03.003.","journal-title":"Hum Pathol"},{"issue":"32","key":"753_CR8","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1200\/jco.2008.18.1107","volume":"26","author":"K Levanon","year":"2008","unstructured":"Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284\u201393. https:\/\/doi.org\/10.1200\/jco.2008.18.1107.","journal-title":"J Clin Oncol"},{"issue":"7353","key":"753_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"issue":"2","key":"753_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/jop.0924603","volume":"5","author":"RF Morton","year":"2009","unstructured":"Morton RF, Hammond EH. ASCO provisional clinical opinion: KRAS, cetuximab, and panitumumab: clinical implications in colorectal cancer. J Oncol Pract. 2009;5(2):71\u20132. https:\/\/doi.org\/10.1200\/jop.0924603.","journal-title":"J Oncol Pract"},{"issue":"12","key":"753_CR11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1200\/jco.2009.21.9170","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091\u20136. https:\/\/doi.org\/10.1200\/jco.2009.21.9170.","journal-title":"J Clin Oncol"},{"issue":"11","key":"753_CR12","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/1878-0261.12550","volume":"13","author":"EJ van Helden","year":"2019","unstructured":"van Helden EJ, Angus L, Van Oordt MCHW, Heideman DAM, Boon E, van Es SC, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS. Mol Oncol. 2019;13(11):2361\u201374. https:\/\/doi.org\/10.1002\/1878-0261.12550.","journal-title":"Mol Oncol."},{"issue":"6","key":"753_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/jco.2009.21.9618","volume":"28","author":"TJ Lynch","year":"2010","unstructured":"Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28(6):911\u20137. https:\/\/doi.org\/10.1200\/jco.2009.21.9618.","journal-title":"J Clin Oncol"},{"issue":"13","key":"753_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/s1470-2045(13)70473-x","volume":"14","author":"ES Kim","year":"2013","unstructured":"Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14(13):1326\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(13)70473-x.","journal-title":"Lancet Oncol"},{"issue":"1","key":"753_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s1470-2045(17)30694-0","volume":"19","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018;19(1):101\u201314. https:\/\/doi.org\/10.1016\/s1470-2045(17)30694-0.","journal-title":"Lancet Oncol"},{"issue":"1","key":"753_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1470-2045(11)70318-7","volume":"13","author":"R Pirker","year":"2012","unstructured":"Pirker R, Pereira JR, Von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(11)70318-7.","journal-title":"Lancet Oncol"},{"issue":"20","key":"753_CR17","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/jco.2012.46.2408","volume":"31","author":"J Baselga","year":"2013","unstructured":"Baselga J, G\u00f3mez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013;31(20):2586\u201392. https:\/\/doi.org\/10.1200\/jco.2012.46.2408.","journal-title":"J Clin Oncol"},{"issue":"1","key":"753_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ygyno.2008.12.003","volume":"113","author":"RJ Schilder","year":"2009","unstructured":"Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009;113(1):21\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2008.12.003.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"753_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2007.11.029","volume":"108","author":"AA Secord","year":"2008","unstructured":"Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study. Gynecol Oncol. 2008;108(3):493\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.029.","journal-title":"Gynecol Oncol"},{"key":"753_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00122","volume":"2","author":"PK Mangat","year":"2018","unstructured":"Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2018;2:1\u201314. https:\/\/doi.org\/10.1200\/po.18.00122.","journal-title":"JCO Precis Oncol"},{"key":"753_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.19.00124","volume":"3","author":"T Al Baghdadi","year":"2019","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2019;3:1\u20138. https:\/\/doi.org\/10.1200\/po.19.00124.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"753_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/s1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(10)70130-3.","journal-title":"Lancet Oncol"},{"issue":"8","key":"753_CR23","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.can-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992\u20135. https:\/\/doi.org\/10.1158\/0008-5472.can-06-0191.","journal-title":"Cancer Res"},{"issue":"7","key":"753_CR24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3109\/0284186x.2014.895036","volume":"53","author":"C Therkildsen","year":"2014","unstructured":"Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852\u201364. https:\/\/doi.org\/10.3109\/0284186x.2014.895036.","journal-title":"Acta Oncol"},{"issue":"1","key":"753_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158(1):185\u201397. https:\/\/doi.org\/10.1016\/j.cell.2014.06.003.","journal-title":"Cell"},{"issue":"1","key":"753_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","volume":"158","author":"DD Shao","year":"2014","unstructured":"Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171\u201384. https:\/\/doi.org\/10.1016\/j.cell.2014.06.004.","journal-title":"Cell"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00753-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:48:56Z","timestamp":1634863736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00753-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"22 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cetuximab (Erbitux<sup>\u00ae<\/sup>) and funding for this study were provided by Eli Lilly and Company. Additional funding was provided by AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The American Society of Clinical Oncology receives research support for the Targeted Agent and Profiling Utilization Registry (TAPUR) Study from the following companies: AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Eli Lilly, Merck, and Pfizer. Susan Halabi receives partial grant support by the American Society of Clinical Oncology\u2019s TAPUR. Tareq Al Baghdadi has participated in a consulting day with Bristol-Myers Squibb. Nicole Fleming has participated in a consulting day with Bristol-Myers Squibb and Pfizer. Julie Fisher, David Tait, Elizabeth Garrett-Mayer, Pam K. Mangat, Julian Schink, Ricardo H. Alvarez, Dan Veljovich, Timothy L. Cannon, Pamela Crilley, Theodore Pollock, Carmen Calfa, Ramya Thota, Jared A. Cotta, Andrew L. Rygiel, Sasha Warren, and Richard L. Schilsky have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by a central institutional review board and, in some cases, by a local institutional review board at participating sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided written consent before engaging in study-related activities or providing study data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed an informed consent regarding the publishing of their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JF, DT, EG-M, PKM, and RLS contributed to the conception and design of this article. JF, DT, JS, RHA, DV, TLC, PC, TP, CC, TAB, RT, NF, and JAC contributed by providing study materials. EG-M, PKM, ALR, and SW contributed to this article by collecting and\/or assembling data. SH, EG-M, PKM, ALR, and RLS provided the data analysis and interpretation. JF, DT, EG-M, SH, PKM, TLC, TAB, SW, and RLS contributed to the writing and\/or revision of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}